HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CA-4948

Also Known As:

6'-Amino-N-(2-(morpholin-4-yl)-(1,3)oxazolo(4,5-b)pyridin-6-yl)-(2,3'-bipyridine)-6-carboxamide

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - Morpholines: 6
      - CA-4948: 4

Experts

1.	Agarwal, Beamon: 1 article (01/2022)
2.	Aluri, Srinivas: 1 article (01/2022)
3.	Bhagat, Tushar D: 1 article (01/2022)
4.	Carbajal, Milagros: 1 article (01/2022)
5.	Chen, Xiaoyi: 1 article (01/2022)
6.	Choudhary, Gaurav: 1 article (01/2022)
7.	Gordon-Mitchell, Shanisha: 1 article (01/2022)
8.	Maitra, Anirban: 1 article (01/2022)
9.	Martell, Robert: 1 article (01/2022)
10.	Pradhan, Kith: 1 article (01/2022)

Related Diseases

1.	Hematologic Neoplasms (Hematological Malignancy) 12/10/2020 - "Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies." 01/01/2022 - "The molecule used to block IRAK4, CA-4948 – also known as Emavusertib – is currently being evaluated in clinical trials for myelodysplastic syndromes and other types of blood cancer. " 12/10/2020 - "The overall profile of CA-4948 prompted us to select it as a clinical candidate for evaluation in patients with relapsed or refractory hematologic malignancies including non-Hodgkin lymphoma and acute myeloid leukemia."
2.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/01/2022 - "The molecule used to block IRAK4, CA-4948 – also known as Emavusertib – is currently being evaluated in clinical trials for myelodysplastic syndromes and other types of blood cancer. "
3.	Lymphoma (Lymphomas) 01/01/2023 - "CA-4948 is currently being investigated in clinical trials for relapsed and refractory lymphoma and warrants further translation into PCNSL and MBM." 01/01/2023 - "Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases."
4.	Neoplasms (Cancer) 01/01/2023 - "We next determined the central nervous system (CNS) applicability of CA-4948 in naïve and tumor-bearing mice using models of PCNSL and MBM. " 01/01/2023 - "The inhibition of IRAK-4 with CA-4948 downregulates the expression of important transcription factors involved in tumor growth and proliferation. " 01/01/2023 - "Treatment of tumor-bearing animals with CA-4948 results in the downregulation of mitogen-activated protein kinase (MAPK) signaling in addition to decreased NF-κB. " 12/10/2020 - "CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation. "
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/10/2020 - "The overall profile of CA-4948 prompted us to select it as a clinical candidate for evaluation in patients with relapsed or refractory hematologic malignancies including non-Hodgkin lymphoma and acute myeloid leukemia."

Related Drugs and Biologics

1.	Interleukin-1 Receptor-Associated Kinases
2.	Mitogen-Activated Protein Kinases
3.	Transcription Factors (Transcription Factor)
4.	Phosphotransferases (Kinase)